WC500165698
WC500165698
WC500165698
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Additional European<br />
experts participating at<br />
the meeting for specific<br />
Agenda items<br />
Country<br />
Stefan Bonne<br />
Brune De Schuiteneer<br />
Jamila Hamdani<br />
Cécile Lescrainier<br />
Javier Sawchik<br />
Romana Hašková<br />
Nathalie Dumarcet<br />
Gaëlle Guyader<br />
Caroline Semaille<br />
Massimo Cirillo<br />
Giuseppe Rosano<br />
Jacoline Bouvy<br />
Cristel Loeb<br />
Jarno Hoekman<br />
Maarten Simoons<br />
Maria Vanenburg<br />
Tamar Wohlfarth<br />
Charlotte Backman<br />
Anne Ambrose<br />
Julie Beynon<br />
Phil Bryan<br />
Claire Doe<br />
Raquel Rogers<br />
Catherine Tregunno<br />
Belgium<br />
Belgium<br />
Belgium<br />
Belgium<br />
Belgium<br />
Czech Republic<br />
France<br />
France<br />
France<br />
Italy<br />
Italy<br />
Netherlands<br />
Netherlands<br />
Netherlands<br />
Netherlands<br />
Netherlands<br />
Netherlands<br />
Sweden<br />
United Kingdom<br />
United Kingdom<br />
United Kingdom<br />
United Kingdom<br />
United Kingdom<br />
United Kingdom<br />
No restrictions were identified for the participation of<br />
European experts attending the PRAC meeting<br />
for discussion on specific agenda items<br />
Health care<br />
professiona<br />
ls and<br />
patients<br />
members<br />
Country<br />
Outcome restriction following<br />
evaluation of e-DoI for the meeting:<br />
Topics on the current<br />
Committee Agenda<br />
for which restriction<br />
applies<br />
Product/substance<br />
Filip Babylon<br />
Full involvement<br />
Marco Greco<br />
Full involvement<br />
Kristen Myhr<br />
Full involvement<br />
ANNEX III – List of abbreviations<br />
For a List of the acronyms and abbreviations used in the PRAC (Pharmacovigilance Risk Assessment<br />
Committee) Minutes used in the PRAC minutes, see:<br />
www.ema.europa.eu<br />
Home>About Us>Committees>PRAC Agendas, minutes and highlights<br />
Pharmacovigilance Risk Assessment Committee (PRAC)<br />
EMA/PRAC/253432/2014 Page 64/64
Change language